The incidence of grade @ or worse adverse events , including deaths , was higher in the necitumumab plus pemetrexed and cisplatin group than in the pemetrexed and cisplatin group ; in particular , deaths regarded as related to study drug were reported in @ ( @ % ) of @ patients in the necitumumab group versus nine ( @ % ) of @ patients in the pemetrexed and cisplatin group .